Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025, for NanoVibronix, Inc. (trading symbol: NAOV). The reporting period is significantly impacted by the consummation of the ENvue Merger on February 14, 2025, which combined NanoVibronix with ENvue Medical Holdings LLC. The company operates in two primary segments: NanoVibronix (non-invasive pain therapy and wound healing devices) and ENvue (enteral feeding systems). The financial statements reflect the consolidation of ENvue and adjustments for two reverse stock splits (1-for-11 in March 2025 and 1-for-10 in August 2025).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $494,000 | $1,519,000 |
| Gross Profit (Loss) | ($35,000) | $334,000 |
| Net Loss | ($3,971,000) | ($5,843,000) |
| Net Loss Available to Common Stockholders | ($500,000) | ($2,372,000) |
| Cash and Cash Equivalents | $4,030,000 (as of June 30, 2025) | N/A |
| Total Assets | $51,482,000 | N/A |
| Total Liabilities | $11,005,000 | N/A |
| Stockholders' Equity | $40,477,000 | N/A |
Debt and Liquidity: As of June 30, 2025, the company held $1,975,000 in loans (primarily the Alpha Note) and a $4,161,000 warrant liability. Cash used in operating activities for the six months ended June 30, 2025, was $4,726,000. The company raised approximately $8.2 million in net proceeds from a Series G Preferred Stock offering in May 2025.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 40% year-over-year for the three months ended June 30, 2025 ($494k vs. $817k), primarily due to reduced sales to the largest distributor, partially offset by the inclusion of ENvue revenues post-merger.
- Operating Expenses Surge: Total operating expenses increased significantly to $3,941,000 for the quarter (from $1,102,000 in 2024). This was driven by merger-related professional fees, the inclusion of ENvue's operations, and a $624,000 clinical trial cost with the University of Michigan.
- Gross Margin Compression: The company reported a gross loss of $35,000 for the quarter, compared to a gross profit of $428,000 in the prior year. This was caused by a $159,000 inventory write-down and $186,000 in technology amortization.
- Balance Sheet Expansion: Total assets grew from $3.6 million to $51.5 million, largely due to the recognition of $38.6 million in goodwill and $5.5 million in intangible assets from the ENvue acquisition.
Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months due to recurring losses and negative cash flows. Future operations depend on raising additional capital.
- Product Halt: The company identified inaccuracies in its 510(k) application for the PainShield MD Plus product and has withdrawn the FDA clearance request, halting future sales. An inventory allowance of $159,000 was recorded.
- Legal Contingency: The company has accrued approximately $2.2 million for an arbitration award to Protrade Systems, Inc., related to a breach of distribution agreement. The company is currently appealing the decision.
- Capital Raises: Subsequent to the period end, the company closed a Series H Preferred Stock offering in July 2025, raising $8 million in gross proceeds.
- Accounting Error Correction: The company corrected an immaterial error from the prior quarter regarding warrant modification expense, reclassifying $623,000 from expense to equity.
Investor Verification Checklist
- Capital Adequacy: Verify the sufficiency of the $4.0 million cash balance against the $4.7 million operating cash burn rate and the timeline for future fundraising.
- Merger Integration: Assess the progress of integrating ENvue operations and the realization of projected synergies given the high operating costs.
- Legal Exposure: Monitor the status of the Protrade Systems arbitration appeal and the potential impact of the $2.2 million accrued liability.
- Product Pipeline: Confirm the status of the PainShield MD Plus regulatory withdrawal and the impact on future revenue streams from the NanoVibronix segment.
- Dilution Risk: Review the terms of the Series G, Series H, and Series X Preferred Stock, including anti-dilution provisions and dividend obligations, which may significantly dilute common shareholders.